SUN-123 Biopsychosocial Outcomes in Transgender and Gender Diverse Individuals

Abstract Disclosure: C.A. Muir: None. R. Germanos: None. M. Guttman-Jones: None. E. Man: None. C. Tran: None. Background: Gender affirming hormone treatment (GAHT) is safe and thought to significantly improve health-related outcomes. However, there is limited prospectively-collected data assessing biological, psychological, and social outcomes of transgender and gender diverse people receiving GAHT. Methods: Interim analysis of an ongoing multi-site, prospective, observational study of adolescents and adults commencing GAHT in Sydney, Australia. Physical examination, laboratory testing, and surveys assessing dysphoria (Transgender Congruence Scale; TCS), depression (Beck Depression Inventory; BDI), and anxiety (Generalized Anxiety Disorder 7; GAD-7) were performed at baseline and 6-months after commencement of GAHT, with further assessments planned at 12-months and 24-months. Baseline and 6-month data for participants enrolled to date with data at both time points will be presented. Results: To date, 99 participants are enrolled and study recruitment is ongoing. At time of abstract submission, baseline and 6-month follow-up data are available for 48 participants and reported herein. The sub-cohort of 48 patients had a median age of 23-years (range 16-51). Birth-assigned sex was male (n=18; 38%) and female (n=30; 62%), respectively. Gender identity was varied and self-reported as non-binary (40%), male (23%), female (21%), fluid (2%), and other/unspecified (14%). Psychological comorbidity was high with prevalent depression (38%), ADHD (27%), anxiety (25%), and ASD (10%) diagnoses respectively. Gender dysphoria was assessed using the TCS (scored out of 5, with higher scores equating to higher levels of congruency between an individual’s appearance and gender identity). At baseline, mean TCS measured 2.4 (±0.5). Following 6-months of GAHT, TCS significantly improved to 3.3 (±0.7), indicating lower levels of gender dysphoria (p<0.001). At baseline, depression scores were elevated with a mean BDI of 20 (±11), indicating moderate levels of depression. Following 6-months of GAHT, BDI improved to 14 (±10), indicating mild depression only (p<0.001). Anxiety scores were also elevated at baseline with a mean GAD-7 score of 15 (±6), indicating severe anxiety. Following 6-months of GAHT, GAD-7 significantly improved to 13 (±6), corresponding to moderate levels of anxiety (p=0.006). Conclusion: In preliminary analyses of an ongoing prospective observational study of treatment naïve individuals commencing GAHT, survey measures of gender dysphoria, depression, and anxiety improved significantly across a diverse spectrum of gender identities. Presentation: Sunday, July 13, 2025